Feldan Therapeutics is led by young leaders focused on translating the Feldan Shuttle technology into breakthrough therapies for patients with serious diseases. Our multidisciplinary team has expertise in recombinant protein, advanced protein delivery and genome engineering.
Dr. Francois-Thomas Michaud, Ph.D., Eng.
Chief Executive Officer and Co-founder
Dr. François-Thomas Michaud has served as Chief Executive Officer since 2007. Dr. Michaud has a large responsibility in the growth of the company in which he leads and supervises, with the company directors, all company’s aspects; finance, administration, legal, business development, research and development and production. Mr. Michaud completed a M.Sc. degree on the Development of an intense process for recombinant protein production and earned his Ph.D. in Chemical Engineering at the University Laval.
Dr. Meriem Benchabane, Ph.D.,
Marketing and Business Development Director
Dr. Benchabane joined Feldan in spring 2013 as a Market Intelligence Manager. She is responsible of directing marketing activities and business development team. Her Ph. D. thesis pertained to the production of recombinant therapeutic proteins in plants under a joint supervision between Laval University and University of Rouen (France), and her post-doctoral fellowship at Canadian Natural Resources focused on transcription factors implicated in tree defense reactions.
M. Victor Parent, M.Sc.,
Victor Parent joined Feldan in 2010 as the Production Director. He is in charge of all production activities in the company. M. Parent has completed a B.Sc. degree in chemical engineering. Following the completion of a Master degree, he has undertaken doctoral studies in Chemical engineering at Laval University. Moreover, he has acquired experience in Bioprocess Engineering at PTT PolyCanada and received a Bioengineering Internship to join Genentech in California prior to joining Feldan.
Dr. David Guay, Ph.D.
David Guay joined Feldan in 2009 as R&D director. He is in charge of directing all activities related to the Shuttle Technology. During his Master and Ph.D. training, he studied the implication of the DNA/RNA binding protein YB-1 in chemotherapy resistance. He developed strong molecular and cell biology skills working with DNA, RNA, recombinant proteins and cells. During his postdoctoral fellow at McGill University, in the chemical engineering department, he developed a DNA delivery technique based on a non-thermal plasma technology.